PH12015502302A1 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine - Google Patents

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Info

Publication number
PH12015502302A1
PH12015502302A1 PH12015502302A PH12015502302A PH12015502302A1 PH 12015502302 A1 PH12015502302 A1 PH 12015502302A1 PH 12015502302 A PH12015502302 A PH 12015502302A PH 12015502302 A PH12015502302 A PH 12015502302A PH 12015502302 A1 PH12015502302 A1 PH 12015502302A1
Authority
PH
Philippines
Prior art keywords
olopatadine
mometasone
combination
allergic rhinitis
treatment
Prior art date
Application number
PH12015502302A
Other languages
English (en)
Other versions
PH12015502302B1 (en
Inventor
Khairatkar Joshi Neelima
kulkarni Abhay
Wale Dinesh Pradeep
Bhosale Vikram Mansingh
Agarwal Piyush
Keohane Patrick
Sudeesh K Tantry
Oh Chad
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of PH12015502302A1 publication Critical patent/PH12015502302A1/en
Publication of PH12015502302B1 publication Critical patent/PH12015502302B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12015502302A 2013-10-04 2015-10-05 Treatment of allergic rhinitis using a combination of mometasone and olopatadine PH12015502302B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (2)

Publication Number Publication Date
PH12015502302A1 true PH12015502302A1 (en) 2016-02-15
PH12015502302B1 PH12015502302B1 (en) 2016-02-15

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502302A PH12015502302B1 (en) 2013-10-04 2015-10-05 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553A1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302B1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP2922553A1 (en) * 2013-10-04 2015-09-30 Glenmark Pharmaceuticals Limited Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
DK3468532T3 (da) * 2017-06-28 2021-01-04 Glenmark Specialty Sa Dispenseranordning og farmaceutisk sammensætning til behandling af rhinitis
AU2019224850B2 (en) * 2018-02-23 2024-11-28 Glenmark Specialty S.A. Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
JP2006508138A (ja) * 2002-11-12 2006-03-09 アルコン,インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DK1814538T3 (da) 2004-11-24 2009-11-02 Alcon Inc Fremgangsmåde til administration af næsespray
EP1919450B1 (en) 2005-09-01 2014-06-11 Meda AB Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
WO2007064912A2 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
HUE036777T2 (hu) 2006-04-21 2018-07-30 Toko Yakuhin Kogyo Kk Bõrhöz/nyálkahártyához tapadó porlasztható gél típusú preparátum és adagolási rendszer a preparátum alkalmazásával
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
JP2011528355A (ja) 2008-07-15 2011-11-17 シェーリング コーポレイション 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2011008923A2 (en) 2009-07-17 2011-01-20 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN103269687B (zh) 2011-01-04 2016-09-14 伊斯塔制药公司 贝托斯汀组合物
MX2015005081A (es) 2012-10-25 2015-07-17 Novozymes As Metodo mejorado para el lavado manual de la vajilla.
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
SMT202100563T1 (it) * 2013-09-13 2021-11-12 Glenmark Specialty Sa Composizione farmaceutica stabile a dose fissa comprendente mometasone e olopatadina per la somministrazione nasale
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP2922553A1 (en) * 2013-10-04 2015-09-30 Glenmark Pharmaceuticals Limited Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Also Published As

Publication number Publication date
RU2015128496A (ru) 2017-11-13
JP2018123157A (ja) 2018-08-09
JP2020097624A (ja) 2020-06-25
MX2015009429A (es) 2015-10-09
US10646500B2 (en) 2020-05-12
WO2015049665A1 (en) 2015-04-09
CN112773808A (zh) 2021-05-11
JP2016531949A (ja) 2016-10-13
JP6768733B2 (ja) 2020-10-14
RU2019104453A (ru) 2019-03-28
EP4272839A3 (en) 2024-01-03
EP4272839A2 (en) 2023-11-08
RU2015128496A3 (enExample) 2018-06-19
CN105792828A (zh) 2016-07-20
HK1215674A1 (zh) 2016-09-09
MY176808A (en) 2020-08-21
PH12015502302B1 (en) 2016-02-15
RU2686670C2 (ru) 2019-04-30
MX2020003035A (es) 2020-07-22
EP2922553A1 (en) 2015-09-30
US20150099725A1 (en) 2015-04-09
JP6419195B2 (ja) 2018-11-07
ZA201504740B (en) 2016-10-26
UA120587C2 (uk) 2020-01-10

Similar Documents

Publication Publication Date Title
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
HRP20181169T1 (hr) Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti
GB201320723D0 (en) Composition and methods of treatment
EP3013407A4 (en) Medical treatment system and method of use
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EP3084000A4 (en) Method of diagnosis and treatment
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
EP2948195A4 (en) INCLUDED DEVICES FOR THE TREATMENT OF MEDICAL WASTE AND METHOD FOR THE USE THEREOF
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
GB201410954D0 (en) Skin treatment devices and methods